Skip to main content
. 2022 Jul 29;9:916156. doi: 10.3389/fcvm.2022.916156

Figure 5.

Figure 5

Kaplan-Meier plots of (A) pulmonary embolism rates, (B) stroke rates and (C) myocardial infarction rates of controls vs. patients treated with DOAC and dipyridamole.